Table 3.
Incidence of cardiac adverse events (grades ≥3) in trastuzumab-treated younger (<65 years), older (65–74 years), and elderly (≥65 years) patients
| Adverse event, n (%) | Age (years) at MBC | ||
|---|---|---|---|
| <65 (n = 746) | 65–74 (n = 134) | ≥75 (n = 63) | |
| Any | 51 (6.8) | 9 (6.7) | 16 (25.4) |
| Angina pectoris | 1 (0.13) | 1 (0.75) | 0 (0.0) |
| Atrial arrhythmia | 2 (0.27) | 1 (0.75) | 2 (3.1) |
| Cardiac disorder (NOS) | 8 (1.1) | 2 (1.5) | 4 (6.3) |
| Congestive heart failure | 14 (1.9) | 2 (1.5) | 2 (3.2) |
| Left ventricular dysfunction | 21 (2.8) | 2 (1.5) | 3 (4.8) |
| Myocardial infarction | 1 (0.13) | 1 (0.75) | 2 (3.2) |
| Pericardial effusion | 4 (0.53) | 0 (0.0) | 2 (3.2) |
| Ventricular arrhythmia | 0 (0.0) | 0 (0.0) | 1 (1.6) |
NOS not otherwise specified